Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Nov 10:8:255-67.
doi: 10.2147/BTT.S29947. eCollection 2014.

Targeted alpha anticancer therapies: update and future prospects

Barry J Allen  1 , Chen-Yu Huang  2 , Raymond A Clarke  3
Affiliations
Review

Targeted alpha anticancer therapies: update and future prospects

Barry J Allen et al. Biologics. .

Abstract

Targeted alpha therapy (TAT) is an emerging option for local and systemic cancer treatment. Preclinical research and clinical trials show that alpha-emitting radionuclides can kill targeted cancer cells while sparing normal cells, thus reducing toxicity. (223)RaCl2 (Xofigo(®)) is the first alpha emitting radioisotope to gain registration in the US for palliative therapy of prostate cancer bone metastases by indirect physiological targeting. The alpha emitting radioisotopes (211)At, (213)Bi, (225)Ac and (227)Th are being used to label targeting vectors such as monoclonal antibodies for specific cancer therapy indications. In this review, safety and tolerance aspects are considered with respect to microdosimetry, specific energy, Monte Carlo model calculations, biodosimetry, equivalent dose and mutagenesis. The clinical efficacy of TAT for solid tumors may also be enhanced by its capacity for tumor anti-vascular (TAVAT) effects. This review emphasizes key aspects of TAT research with respect to the PAI2-uPAR complex and the monoclonal antibodies bevacizumab, C595 and J591. Clinical trial outcomes are reviewed for neuroendocrine tumors, leukemia, glioma, melanoma, non-Hodgkins lymphoma, and prostate bone metastases. Recommendations and future directions are proposed.

Keywords: C595; J591; PAI2; bevacizumab; biodosimetry; cancer; metastases; microdosimetry; mutagenesis; tumors.

PubMed Disclaimer

References

    1. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495–497. - PubMed
    1. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J. Nucl Med. 2002;43(5):693–713. - PubMed
    1. Brons S, Jakob B, Taucher-Scholz G, Kraft G. Heavy ion production of single- and double-strand breaks in plasmid DNA in aqueous solution. Phys Med. 2001;17(Suppl 1):217–218. - PubMed
    1. Kerr JF. A histochemical study of hypertrophy and ischaemic injury of rat liver with special reference to changes in lysosomes. J Pathol Bacteriol. 1965;90(2):419–435. - PubMed
    1. Elgqvist J. Targeted Alpha Therapy. Current Radiopharmaceuticals. 2011;4(3):176. - PubMed

LinkOut - more resources